RHHBF - Bicycle Therapeutics: Platform Technology Has Potential; Move To Combination Therapy With Opdivo Is Next
- Positive interim data was achieved using BT5528 for the treatment of patients with advanced solid tumors.
- Positive preliminary data was achieved using BT8009 for the treatment of patients with advanced solid tumors.
- I believe that the addition of Opdivo for each BT8009 and BT5528 holds the potential to help patients achieve higher response rates.
- Two highly established partnerships with Roche and Ionis Pharmaceuticals proves the value of "Bicycles" as a drug technology which may boost response rates for cancer patients.
- Bicycle Therapeutics had $259.5 million in cash as of September 30, 2021; It believes that it has enough cash on hand to fund its operations for at least the next 12 months from November of 2021.
For further details see:
Bicycle Therapeutics: Platform Technology Has Potential; Move To Combination Therapy With Opdivo Is Next